Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations

Stem Cells and Development

Volumn 23, Issue 7, 2014, Pages 755-766

  Ungerer, Christopher ^a   Quade Lyssy, Patricia ^a   Radeke, Heinfried H ^a   Henschler, Reinhard ^a,b   Königs, Christoph ^c   Köhl, Ulrike ^d   Seifried, Erhard ^a   Schüttrumpf, Jörg ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 8; ECALECTIN; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS ASSAY; ARTICLE; B LYMPHOCYTE; BLOOD CLOTTING; CELL TYPE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TITRIMETRY; UPREGULATION; WESTERN BLOTTING;

ADULT; ANIMALS; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELL PROLIFERATION; CELLS, CULTURED; FACTOR VIII; FEMALE; GALECTINS; GENE EXPRESSION; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOMODULATION; INTERFERON-GAMMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES;

EID: 84897428993     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0335     Document Type: Article

References (60)

1. Campagnoli C, IA Roberts, S Kumar, PR Bennett, I Bellantuono and NM Fisk. (2001). Identification of mesenchymal stem/progenitor cells in human first-Trimester fetal blood, liver, and bone marrow. Blood 98:2396-2402.
2. in 't Anker PS, WA Noort, SA Scherjon, C Kleijburg-van der Keur, AB Kruisselbrink, RL van Bezooijen, W Beekhuizen, R Willemze, HH Kanhai and WE Fibbe. (2003). Mesenchymal stem cells in human second-Trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88:845-852.
3. Caplan AI. (1991). Mesenchymal stem cells. J Orthop Res 9:641-650.
4. Ciapetti G, D Granchi and N Baldini. (2012). The combined use of mesenchymal stromal cells and scaffolds for bone repair. Curr Pharm Des 18:1796-1820.
5. Lee RH, AA Pulin, MJ Seo, DJ Kota, J Ylostalo, BL Larson, L Semprun-Prieto, P Delafontaine and DJ Prockop. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5:54-63.
6. Bassi EJ, CA Aita and NO Camara. (2011). Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand?. World J Stem Cells 3:1-8.
7. Yanez R, ML Lamana, J Garcia-Castro, I Colmenero, M Ramirez and JA Bueren. (2006). Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 24:2582-2591.
8. Zhang J, Y Li, J Chen, Y Cui, M Lu, SB Elias, JB Mitchell, L Hammill, P Vanguri and M Chopp. (2005). Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 195:16-26.
9. Griffin MD, T Ritter and BP Mahon. (2010). Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 21:1641-1655.
10. Le Blanc K, I Rasmusson, B Sundberg, C Gotherstrom, M Hassan, M Uzunel and O Ringden. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
11. Wang S, X Qu and RC Zhao. (2012). Clinical applications of mesenchymal stem cells. J Hematol Oncol 5:19.
12. Nauta AJ and WE Fibbe. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499-3506.
13. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
14. Tse WT, JD Pendleton, WM Beyer, MC Egalka and EC Guinan. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation 75:389-397.
15. Meisel R, A Zibert, M Laryea, U Gobel, W Daubener and D Dilloo. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 103:4619-4621.
16. Ryan JM, F Barry, JM Murphy and BP Mahon. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149:353-363.
17. Gieseke F, J Bohringer, R Bussolari, M Dominici, R Handgretinger and I Muller. (2010). Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116:3770-3779.
18. Sioud M, A Mobergslien, A Boudabous and Y Floisand. (2010). Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand J Immunol 71:267-274.
19. Thijssen VL, F Poirier, LG Baum and AW Griffioen. (2007). Galectins in the tumor endothelium: Opportunities for combined cancer therapy. Blood 110:2819-2827.
20. Grigorian A, S Torossian and M Demetriou. (2009). T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol Rev 230:232-246.
21. Wada J and YS Kanwar. (1997). Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 272:6078-6086.
22. Dardalhon V, AC Anderson, J Karman, L Apetoh, R Chandwaskar, DH Lee, M Cornejo, N Nishi, A Yamauchi, et al. (2010). Tim-3/galectin-9 pathway: Regulation of Th1 immunity through promotion of CD11b + Ly-6G + myeloid cells. J Immunol 185:1383-1392.
23. Bi S, PW Hong, B Lee and LG Baum. (2011). Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A 108:10650-10655.
24. Asakura H, Y Kashio, K Nakamura, M Seki, S Dai, Y Shirato, MJ Abedin, N Yoshida, N Nishi, et al. (2002). Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol 169:5912-5918.
25. Imaizumi T, M Kumagai, N Sasaki, H Kurotaki, F Mori, M Seki, N Nishi, K Fujimoto, K Tanji, et al. (2002). Interferongamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol 72:486-491.
26. Sakai K, E Kawata, E Ashihara, Y Nakagawa, A Yamauchi, H Yao, R Nagao, R Tanaka, A Yokota, et al. (2011). Galectin-9 ameliorates acute GVH disease through the induction of Tcell apoptosis. Eur J Immunol 41:67-75.
27. Lee SB, A Schramme, K Doberstein, R Dummer, MS Abdel-Bakky, S Keller, P Altevogt, ST Oh, J Reichrath, et al. (2010). ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol 130:763-773.
28. Milanov P, L Ivanciu, D Abriss, P Quade-Lyssy, W Miesbach, S Alesci, T Tonn, M Grez, E Seifried and J Schuttrumpf. (2012). Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood 119: 602-611.
29. Ciuculescu F, M Giesen, E Deak, V Lang, E Seifried and R Henschler. (2011). Variability in chemokine-induced adhesion of human mesenchymal stromal cells. Cytotherapy 13:1172-1179.
30. Gieseke F, A Kruchen, N Tzaribachev, F Bentzien, M Dominici and I Muller. (2013). Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation. Eur J Immunol 43:2741-2749.
31. Bi S, LA Earl, L Jacobs and LG Baum. (2008). Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J Biol Chem 283:12248-12258.
32. Fibbe WE, AJ Nauta and H Roelofs. (2007). Modulation of immune responses by mesenchymal stem cells. Ann N Y Acad Sci 1106:272-278.
33. Chen K, D Wang, WT Du, ZB Han, H Ren, Y Chi, SG Yang, D Zhu, F Bayard and ZC Han. (2010). Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol 135:448-458.
34. De Miguel MP, S Fuentes-Julian, A Blazquez-Martinez, CY Pascual, MA Aller, J Arias and F Arnalich-Montiel. (2012). Immunosuppressive properties of mesenchymal stem cells: Advances and applications. Curr Mol Med 12:574-591.
35. Ghannam S, C Bouffi, F Djouad, C Jorgensen and D Noel. (2010). Immunosuppression by mesenchymal stem cells: Mechanisms and clinical applications. Stem Cell Res Ther 1:2.
36. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
37. Alam S, H Li, A Margariti, D Martin, A Zampetaki, O Habi, G Cockerill, Y Hu, Q Xu and L Zeng. (2011). Galectin-9 protein expression in endothelial cells is positively regulated by histone deacetylase 3. J Biol Chem 286:44211-44217.
38. Polchert D, J Sobinsky, G Douglas, M Kidd, A Moadsiri, E Reina, K Genrich, S Mehrotra, S Setty, B Smith and A Bartholomew. (2008). IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38:1745-1755.
39. Kronsteiner B, S Wolbank, A Peterbauer, C Hackl, H Redl, M van Griensven and C Gabriel. (2011). Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev 20:2115-2126.
40. Gieseke F, B Schutt, S Viebahn, E Koscielniak,WFriedrich, R Handgretinger and I Muller. (2007). Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood 110:2197-2200.
41. English K. (2013). Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 91:19-26.
42. Ohtsubo K, S Takamatsu, MT Minowa, A Yoshida, M Takeuchi and JD Marth. (2005). Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell 123:1307-1321.
43. Kashio Y, K Nakamura, MJ Abedin, M Seki, N Nishi, N Yoshida, T Nakamura and M Hirashima. (2003). Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 170:3631-3636.
44. Zhu C, AC Anderson, A Schubart, H Xiong, J Imitola, SJ Khoury, XX Zheng, TB Strom and VK Kuchroo. (2005). The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245-1252.
45. Patel SA, JR Meyer, SJ Greco, KE Corcoran, M Bryan and P Rameshwar. (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J Immunol 184:5885-5894.
46. Liu X, X Qu, Y Chen, L Liao, K Cheng, C Shao, M Zenke, A Keating and RC Zhao. (2012). Mesenchymal stem/stromal cells induce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol 189: 1182-1192.
47. Li Y, J Feng, S Geng, H Wei, G Chen, X Li, L Wang, R Wang, H Peng, G Han and B Shen. (2011). The N-And C-Terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. Mol Immunol 48:670-677.
48. Katoh S, N Ishii, A Nobumoto, K Takeshita, SY Dai, R Shinonaga, T Niki, N Nishi, A Tominaga, A Yamauchi and M Hirashima. (2007). Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med 176:27-35.
49. Camp RL, TA Kraus, ML Birkeland and E Pure. (1991). High levels of CD44 expression distinguish virgin from antigenprimed B cells. J Exp Med 173:763-766.
50. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancardi, V Pistoia and A Uccelli. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
51. Rasmusson I, K Le Blanc, B Sundberg and O Ringden. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 65:336-343.
52. Asari S, S Itakura, K Ferreri, CP Liu, Y Kuroda, F Kandeel and Y Mullen. (2009). Mesenchymal stem cells suppress Bcell terminal differentiation. Exp Hematol 37:604-615.
53. Ren G, J Su, L Zhang, X Zhao, W Ling, A L'Huillie, J Zhang, Y Lu, AI Roberts, et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27:1954-1962.
54. Reipert BM, P Allacher, C Hausl, AG Pordes, RU Ahmad, I Lang, J Ilas, J Windyga, A Klukowska, EM Muchitsch and HP Schwarz. (2010). Modulation of factor VIII-specific memory B cells. Haemophilia 16:25-34.
55. Rafei M, J Hsieh, S Fortier, M Li, S Yuan, E Birman, K Forner, MN Boivin, K Doody, et al. (2008). Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 112:4991-4998.
56. Moritoki M, T Kadowaki, T Niki, D Nakano, G Soma, H Mori, H Kobara, T Masaki, M Kohno and M Hirashima. (2013). Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3. PLoS One 8:e60807.
57. Lv K, Y Zhang, M Zhang, M Zhong and Q Suo. (2012). Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4 (+) CD25(low/int) effector T-Cell apoptosis and increasing regulatory T cell number. PLoS One 7: E48379.
58. Fukushima A, T Sumi, K Fukuda, N Kumagai, T Nishida, K Okumura, H Akiba, H Yagita and H Ueno. (2008). Roles of galectin-9 in the development of experimental allergic conjunctivitis in mice. Int Arch Allergy Immunol 146: 36-43.
59. de Kivit S, E Saeland, AD Kraneveld, HJ van de Kant, B Schouten, BC van Esch, J Knol, AB Sprikkelman, LB van der Aa, et al. (2012). Galectin-9 induced by dietary synbiotics is involved in suppression of allergic symptoms in mice and humans. Allergy 67:343-352.
60. Abdi R, P Fiorina, CN Adra, M Atkinson and MH Sayegh. (2008). Immunomodulation by mesenchymal stem cells: A potential therapeutic strategy for type 1 diabetes. Diabetes 57:1759-1767.